Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Protalix BioTherapeutics (PLX) over the last 17 years, with Q1 2025 value amounting to $76.6 million.

  • Protalix BioTherapeutics' Shares Outstanding (Weighted Average) rose 489.54% to $76.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $76.6 million, marking a year-over-year increase of 489.54%. This contributed to the annual value of $48.5 million for FY2022, which is 981.4% up from last year.
  • According to the latest figures from Q1 2025, Protalix BioTherapeutics' Shares Outstanding (Weighted Average) is $76.6 million, which was up 489.54% from $73.3 million recorded in Q2 2024.
  • Protalix BioTherapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $76.6 million for Q1 2025, and its period low was $39.9 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $48.5 million (2022), whereas its average is $54.9 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Shares Outstanding (Weighted Average) soared by 12975.55% in 2021, and later soared by 416.19% in 2022.
  • Protalix BioTherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $44.1 million in 2021, then increased by 9.81% to $48.5 million in 2022, then soared by 38.55% to $67.2 million in 2023, then rose by 9.16% to $73.3 million in 2024, then rose by 4.51% to $76.6 million in 2025.
  • Its last three reported values are $76.6 million in Q1 2025, $73.3 million for Q2 2024, and $73.0 million during Q1 2024.